Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- 0 vs. Q1 2025
- Shares held
- 23.8M
- +1.27M (+5.6%) vs. Q1 2025
- Total value
- $16.2M
- −$139.5K (−0.9%) vs. Q1 2025
- New holders
- 5
- 4 more added
- Sold out
- 5
- 11 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 9,105,451 | $6.19M | 0.48% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.10M | 0.39% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.01M | 0.47% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.00M | 5.13% | 00.0% | Unchanged |
| Morgan Stanley | 1,444,326 | $982.0K | 0.00% | +288,488+25.0% | Added |
| Ghisallo Capital Management LLC | 1,333,000 | $906.3K | 0.02% | +1,333,000 | New |
| Vanguard Group Inc | 1,151,023 | $782.7K | 0.00% | +15,307+1.3% | Added |
| AJU IB Investment Co., Ltd. | 667,742 | $454.0K | 0.49% | 00.0% | Unchanged |
| FMR LLC | 511,820 | $348.0K | 0.00% | −372,215−42.1% | Reduced |
| Geode Capital Management, LLC | 369,660 | $251.4K | 0.00% | −9,356−2.5% | Reduced |
| Trustees of Columbia University in the City of New York | 249,635 | $169.8K | 0.02% | 00.0% | Unchanged |
| UBS Group AG | 239,969 | $163.2K | 0.00% | +76,868+47.1% | Added |
| Squarepoint Ops LLC | 235,456 | $160.1K | 0.00% | +235,456 | New |
| Balyasny Asset Management LLC | 198,859 | $135.2K | 0.00% | −55,487−21.8% | Reduced |
| Renaissance Technologies LLC | 164,200 | $111.6K | 0.00% | −13,500−7.6% | Reduced |
| Avantax Planning Partners, Inc. | 142,338 | $96.8K | 0.00% | −8,061−5.4% | Reduced |
| Two Sigma Investments, LP | 78,032 | $53.1K | 0.00% | −6,036−7.2% | Reduced |
| Northern Trust Corp | 66,609 | $45.3K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 56,081 | $38.1K | 0.00% | −15,000−21.1% | Reduced |
| State Street Corp | 43,390 | $29.5K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 34,721 | $23.6K | 0.00% | +34,721 | New |
| LPL Financial LLC | 31,000 | $21.1K | 0.00% | +31,000 | New |
| SevenBridge Financial Group, LLC | 25,000 | $17.5K | 0.00% | −21,000−45.7% | Reduced |
| Aptus Capital Advisors, LLC | 25,000 | $17.0K | 0.00% | −21,000−45.7% | Reduced |
| Mariner, LLC | 25,000 | $17.0K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 18,761 | $12.8K | 0.00% | −15,200−44.8% | Reduced |
| Tower Research Capital LLC (TRC) | 15,412 | $10.5K | 0.00% | +15,412 | New |
| Dunhill Financial, LLC | 10,274 | $6.99K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $6.80K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $6.80K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.24K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,037 | $1.39K | 0.00% | −72,663−97.3% | Reduced |
| Key Financial Inc | 830 | $564 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 331 | $225 | 0.00% | +41+14.1% | Added |
| Private Wealth Management Group, LLC | 310 | $211 | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −51,110−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −42,546−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −62−100.0% | Sold out |